Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07372625 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

A Phase 1 study of Advanced Solid Tumors and TP53 Y220C Mutation, sponsored by PMV Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
14
Enrollment target
5
Study locations

NCT07372625 is a Phase 1 study of Advanced Solid Tumors and TP53 Y220C Mutation that is actively recruiting participants, run by PMV Pharmaceuticals. The registered enrollment target is 14 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (93% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07372625, a Phase 1 study of Advanced Solid Tumors and TP53 Y220C Mutation, is actively recruiting participants, sponsored by PMV Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
14 participants
Enrollment target
5
Study locations

Study Summary

This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.

Conditions Studied

Advanced Solid Tumors TP53 Y220C Mutation

Interventions

  • DRUG rezatapopt
  • DRUG metformin hydrochloride 500 mg tablet
  • DRUG rosuvastatin 10 mg tablet
  • DRUG repaglinide 0.5 mg tablet
  • DRUG midazolam hydrochloride syrup

Study Locations (5)

Texas

  • SCRI at Mary Crowley - Dallas
  • NEXT Oncology - San Antonio

Colorado

  • HealthOne Denver - Denver

Florida

  • Florida Cancer Specialists - Orlando

Tennessee

  • SCRI Oncology Partners - Nashville

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2026-02-04
Est. Completion 2028-01
Phase Phase 1

Sponsor

PMV Pharmaceuticals

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07372625

The ClinicalTrials.gov registry entry for NCT07372625 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (93% lower). The listed sponsor is PMV Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which rezatapopt is the first listed.

NCT07372625 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT07372625 about?

NCT07372625 is a clinical study titled "A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.". This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.

What is the current status of trial NCT07372625?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2026-02-04. Estimated completion is 2028-01.

What conditions does trial NCT07372625 study?

This clinical trial studies the following conditions: Advanced Solid Tumors, TP53 Y220C Mutation.

What interventions are being tested in trial NCT07372625?

The interventions under investigation include: rezatapopt (DRUG), metformin hydrochloride 500 mg tablet (DRUG), rosuvastatin 10 mg tablet (DRUG), repaglinide 0.5 mg tablet (DRUG), midazolam hydrochloride syrup (DRUG).

Who is sponsoring clinical trial NCT07372625?

This trial is sponsored by PMV Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07372625 being conducted?

This trial has 5 study locations across Colorado, Florida, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

TP53 Y220C Mutation

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.